AKRO News and Press, Akero Therapeutics Inc. From 11/26/19

The biotech sector continues to grow as valuations are sky high, based on recent M&A’s within the industry. 2019 started off with a boom with the announcement of two multi-billion-dollar deals valued at a total $82 billion, one of them being among the top 10 highest valuations of a...

SAN FRANCISCO , Nov. 13, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that...

Akero Therapeutics (NASDAQ: AKRO ): Q3 GAAP EPS of -$0.56 misses by $0.14 . Cash and cash equivalents of $147.8M Press Release More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN FRANCISCO , Nov. 12, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today reported third...

SCHLIEREN, Switzerland , Nov. 4, 2019 /PRNewswire/ --  InSphero AG  today announced the company received an award at the 2019 Sino-European Innovation Week in Healthcare Technology (SEIWHT) meeting held in Nanjing , China . At the event, InSphero highlighted its 3D InSight&...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

SAN FRANCISCO , Sept. 4, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced...

WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 1...

Akero Therapeutics (NASDAQ: AKRO ): Q2 GAAP EPS of -$2.21 misses by $1.76 . Cash and cash equivalents of $162.6M Press Release More news on: Akero Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,